Aerovate Therapeutics (AVTE)
(Real Time Quote from BATS)
$20.04 USD
+0.13 (0.65%)
Updated Jun 7, 2024 10:02 AM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
AVTE 20.04 +0.13(0.65%)
Will AVTE be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for AVTE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for AVTE
Analysts Have Conflicting Sentiments on These Healthcare Companies: 60 Degrees Pharmaceuticals, Inc. (SXTP) and Aerovate Therapeutics (AVTE)
Notable Wednesday Option Activity: AVTE, MDGL, BASE
Jefferies Sticks to Its Buy Rating for Aerovate Therapeutics (AVTE)
Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Aerovate Therapeutics (AVTE)
Analysts Are Bullish on Top Healthcare Stocks: Ascendis Pharma (ASND), Aerovate Therapeutics (AVTE)